The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and InogenZacks Investment Research • 12/12/24
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And GlaukosBenzinga • 12/02/24
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/05/24
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain HeadwindsBenzinga • 11/05/24
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat EstimatesZacks Investment Research • 11/05/24
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/28/24
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for EpioxaZacks Investment Research • 10/17/24
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and SafetyBusiness Wire • 10/16/24
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual MeetingBusiness Wire • 10/14/24
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4Business Wire • 10/09/24
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option AgreementGlobeNewsWire • 09/23/24